Citigroup Inc. Analysts Give Kura Oncology, Inc. (KURA) a $13.00 Price Target
Kura Oncology, Inc. (NASDAQ:KURA) has been assigned a $13.00 price target by investment analysts at Citigroup Inc. in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the stock. Citigroup Inc.’s target price points to a potential upside of 42.86% from the stock’s current price.
Other equities analysts also recently issued research reports about the stock. Oppenheimer Holdings, Inc. set a $16.00 price objective on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Wednesday, June 14th. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Thursday, May 18th. Finally, Cann reaffirmed a “buy” rating and set a $16.00 price target on shares of Kura Oncology in a research note on Monday, May 15th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $14.60.
Shares of Kura Oncology (NASDAQ:KURA) opened at 9.10 on Tuesday. The stock has a 50 day moving average of $9.13 and a 200-day moving average of $8.64. Kura Oncology has a 1-year low of $4.00 and a 1-year high of $12.10. The firm’s market cap is $178.97 million.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.03. Equities analysts anticipate that Kura Oncology will post ($1.64) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Citigroup Inc. Analysts Give Kura Oncology, Inc. (KURA) a $13.00 Price Target” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/kura-oncology-inc-nasdaqkura-pt-set-at-13-00-by-citigroup-inc.html.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Alethea Capital Management LLC raised its position in shares of Kura Oncology by 128.1% in the second quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after buying an additional 108,577 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Kura Oncology during the second quarter valued at $291,000. State of Wisconsin Investment Board bought a new position in shares of Kura Oncology during the second quarter valued at $102,000. Rhumbline Advisers bought a new position in shares of Kura Oncology during the second quarter valued at $131,000. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of Kura Oncology during the second quarter valued at $226,000. Institutional investors and hedge funds own 50.17% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.